RALLYBIO
Rallybio is a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases. Since its launch in January 2018, Rallybio has built a portfolio of promising product candidates, which are now in development to address rare diseases in the areas of hematology, immuno-inflammation, maternal fetal health and metabolic disorders. The Company’s mission is being advanced by a team of highly experienced biopharma industry leaders with extensive research, development, and rare disease expertise.
RALLYBIO
Industry:
Biopharma Biotechnology Health Care Therapeutics
Founded:
2018-01-01
Address:
Farmington, Connecticut, United States
Country:
United States
Website Url:
http://www.rallybio.com
Total Employee:
11+
Status:
Active
Contact:
(203) 859-3820
Total Funding:
182 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
Affinia Therapeutics
Affinia Therapeutics is a biotechnology company developing transformative AAV gene therapies for people with devastating diseases.
Berkeley Lights
Berkeley Lights is a provider of research and development services using micro-droplet technology that change the biological processes.
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
Cellestia
Cellestia is a clinical stage R&D company developing innovative first-in-class therapies to control and modulate pathogenic gene expression.
D2G Oncology
D2G Oncology is a biotechnology company that specializes in relating drugs to genotypes to transform precision cancer therapeutics.
Day One Biopharmaceuticals
Day One Biopharmaceuticals is a biotechnology company that focuses on developing new cancer therapies for patients of all ages.
Scout Bio
Scout Bi is a biotechnology company that provides veterinary, animal health, and gene therapy.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Global Investment Partners
Global Investment Partners investment in Series B - Rallybio
Canaan Partners
Canaan Partners investment in Series B - Rallybio
New Leaf Venture Partners
New Leaf Venture Partners investment in Series B - Rallybio
5AM Ventures
5AM Ventures investment in Series B - Rallybio
Fairview Capital Partners
Fairview Capital Partners investment in Series B - Rallybio
Solasta Ventures
Solasta Ventures investment in Series B - Rallybio
The Rise Fund
The Rise Fund investment in Series B - Rallybio
Mitsui Global Investment
Mitsui Global Investment investment in Series B - Rallybio
F-Prime Capital
F-Prime Capital investment in Series B - Rallybio
Pivotal bioVenture Partners
Pivotal bioVenture Partners investment in Series B - Rallybio
Official Site Inspections
http://www.rallybio.com Semrush global rank: 10.39 M Semrush visits lastest month: 1
- Host name: 104.21.80.1
- IP address: 104.21.80.1
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Rallybio"
Rallybio
“Our proven team of innovators is advancing multiple clinical and preclinical programs, charting new paths forward that others haven’t tried. We're also searching the globe to find new …See details»
About Us | Rallybio
Rallybio is a clinical-stage biotechnology company built around a team of seasoned industry leaders.See details»
Our Science - Rallybio
We’ve assembled a team with a track record of developing and commercializing therapies for patients with rare diseases. Our success has made us a partner of choice with leaders in industry and in academic clinical centers worldwide.See details»
Rallybio - Crunchbase Company Profile & Funding
Rallybio is an biotechnological research and development services intended to transform the lives of patients with a devastating disease. View contacts for Rallybio to access new leads and connect with decision-makers.See details»
Rallybio - BioCT
Rallybio is an early stage Biotech company incorporated in January 2018. Our ambition is to create a world-leading biotechnology company to transform the lives of patients with …See details»
Rallybio CEO Talks FNAIT and RLYB116 - Patient Worthy
Jan 23, 2024 · Uden now serves as the Co-Founder and Chief Executive Officer (CEO) of Rallybio, a clinical-stage biotechnology company that is working to discover, develop, manufacture, and deliver therapeutics for individuals living …See details»
Rallybio Incorporated! | Rallybio
Jan 5, 2018 · It is our hope that we are able to create a world-leading biotechnology organization that transforms the lives of patients with devastating diseases and built around people with an …See details»
Rallybio to Provide Update on RLYB116 Program, an Innovative ...
3 days ago · Rallybio (NASDAQ: RLYB) is a clinical-stage biotechnology company with a mission to develop and commercialize life-transforming therapies for patients with severe and rare …See details»
Rallybio scores $145M, unveils lead rare disease program
May 19, 2020 · Rallybio found the program, now called RLYB-211, in a worldwide search for assets, acquiring it from a tiny startup in Norway. It’s designed to treat fetal and neonatal alloimmune...See details»
Rallybio - Fierce Pharma
But that’s not stopping New Haven, Connecticut-based Rallybio from rallying scientists and experts against fetal and neonatal alloimmune thrombocytopenia (FNAIT). Co-founded and led …See details»
Rallybio commences Phase II trial for FNAIT in …
6 days ago · Rallybio CEO Stephen Uden said: “The initiation of screening in the RLYB212 Phase II trial is a significant milestone. “We are thrilled to achieve this critical step towards delivering on our mission to prevent maternal …See details»
CREATING PATHS FORWARD - Rallybio
Rallybio’s 2022 RallyTogether document established the following objectives as central to our ESG efforts: • Live our culture and values in a way that makes Rallybio a great place to work • …See details»
Rallybio Reveals Details of Two Pipeline Programs with the …
Mar 2, 2021 · Rallybio plans to submit clinical trial applications for both RLYB212 and RLYB116 in the second half of 2021.See details»
Rallybio Presents Natural History Study for Fetal and Neonatal ...
Rallybio (NASDAQ: RLYB) is a clinical-stage biotechnology company with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases.See details»
J&J, Rallybio join forces in new maternal-fetal disease pact
Apr 10, 2024 · Under the deal, rare disease biotech Rallybio will receive an upfront $500,000 payment from J&J to raise awareness about the pharma's FNAIT therapy program as the …See details»
Rallybio Highlights Portfolio Advances and Outlines Expected …
NEW HAVEN, Conn., January 04, 2024--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life …See details»
Rallybio Announces Initiation of Phase 2 Clinical Trial of RLYB212
Nov 21, 2024 · Rallybio (NASDAQ: RLYB) is a clinical-stage biotechnology company with a mission to develop and commercialize life-transforming therapies for patients with severe and …See details»
Two former Alexion leaders fight through a tough market to …
Nov 5, 2024 · At Rallybio, a biotech with an early-stage candidate for the rare fetal and neonatal alloimmune thrombocytopenia, a disease that arises from an incompatibility between blood …See details»
Careers at Rallybio | Rallybio
Explore the opportunities at Rallybio. We don’t have any open positions right now. The good news is, we expect that to change soon. Please be sure to check back. Unimagined therapies. …See details»
Rallybio Announces Collaboration to Advance Therapeutic …
Apr 10, 2024 · Rallybio is developing RLYB212, a novel human monoclonal anti-HPA-1a antibody designed to prevent pregnant individuals from alloimmunizing 2, thereby eliminating the risk of …See details»